预约演示
更新于：2025-02-07
Pilocarpine Hydrochloride
盐酸毛果芸香碱
更新于：2025-02-07
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 加拿大 (1951-12-31), |
最高研发阶段(中国)临床3期 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C11H17ClN2O2 |
InChIKeyRNAICSBVACLLGM-GNAZCLTHSA-N |
CAS号54-71-7 |
关联
105
项与 盐酸毛果芸香碱 相关的临床试验NCT06783686
Effect on Pupil Size After One-time Administration of NV701 (Pilocarpine 1.25%) Vs. Vuity (Pilocarpine 1.25%)
CTR20244733
盐酸毛果芸香碱滴眼液用于成人老视患者的有效性和安全性的随机、多中心、双盲、安慰剂对照临床试验
CTRI/2024/10/074850
Phase III RCT comparing salivary flow rate of Transcutaneous Electrical Nerve Stimulation (TENS) versus Pilocarpine in patients who are receiving parotid sparing VMAT in Head and Neck Cancer patients - Nil
100 项与 盐酸毛果芸香碱 相关的临床结果
登录后查看更多信息
100 项与 盐酸毛果芸香碱 相关的转化医学
登录后查看更多信息
100 项与 盐酸毛果芸香碱 相关的专利（医药）
登录后查看更多信息
11,044
项与 盐酸毛果芸香碱 相关的文献（医药）2025-03-01BRAIN RESEARCH
Mechanistic insights into Quetiapine’s Protective effects on cognitive function and synaptic plasticity in epileptic rats
Article
作者: Li, Ao ; Xia, Jianxue ; Luo, Dongyang ; Zhang, Xuebing ; Ding, Chenzhe ; Lan, Yanping
The study aimed to examine the effects of Quetiapine, an atypical antipsychotic medication with purported neuroprotective qualities, on cognitive function and synaptic plasticity in epileptic rats. This investigation also sought to elucidate the mechanisms by which quetiapine influences the activity of the cyclic adenylate response element binding protein (CREB)/brain-derived neurotrophic factor (BDNF) signaling pathway and metallomatrix proteinase-9 (MMP9) expression in the context of epilepsy. The epileptic model was induced in rats through the administration of pilocarpine, with normal rats serving as the control group. Within the epilepsy group, two subgroups were established: one receiving normal saline and the other receiving quetiapine. Behavioral assays were utilized to assess learning, memory, and spatial exploration abilities. Furthermore, Western blot analysis, immunohistochemistry (IHC), and immunofluorescence (IF) staining were employed to evaluate the activity of the CREB/BDNF pathway, expression of MMP9 protein, and levels of synaptic plasticity-related proteins. Our study revealed that Quetiapine administration led to a notable enhancement in learning and memory in epileptic rats, as indicated by heightened drinking durations and visitation rates in behavioral assessments. Furthermore, Quetiapine upregulated the expression of pro-BDNF, m-BDNF, p-CREB, and CREB within the hippocampus, along with elevating mRNA levels of BDNF and CREB. Additionally, Quetiapine suppressed MMP-9 expression and promoted synaptic plasticity by augmenting SYN and PSD-95 expression levels in the hippocampus. Therefore, Quetiapine improved cognitive functions such as learning, memory, and spatial exploration in epileptic rats. Moreover, Quetiapine activated the CREB/BDNF signaling pathway, suppressed MMP-9 expression, and promoted synaptic plasticity.
2025-03-01AMERICAN JOURNAL OF OPHTHALMOLOGY
Using Real-World Data to Assess the Association of Retinal Detachment With Topical Pilocarpine Use
Article
作者: Jabbehdari, Sayena ; Phillips, Paul H. ; Jong, Sarah ; Chauhan, Muhammad Z ; Sallam, Ahmed B. ; Chauhan, Muhammad Z. ; Elhusseiny, Abdelrahman M. ; Sallam, Ahmed B ; Phillips, Paul H ; Elhusseiny, Abdelrahman M ; Alshammari, Nayef
PURPOSE:
To examine the association between topical pilocarpine and the risk of new-onset rhegmatogenous retinal detachment (RRD).
DESIGN:
Retrospective clinical cohort study.
METHODS:
We used an aggregated electronic health records research network, TriNetX, to examine the risk of RRD (ICD-10: H33.0x) following the initiation of pilocarpine. The primary study group included adult patients over 40 years who received topical pilocarpine (1.25% or any dose with the exclusion of other indications) for the first time. Our control group consisted of patients with presbyopia who were started on artificial tears and had no history of topical pilocarpine use during the study period. We matched both cohorts using propensity score matching (PSM) based on demographics, systemic comorbidities, and known risk factors for RRD.
RESULTS:
After matching, the three-month risk of RRD was significantly higher in the pilocarpine group (0.53%) compared to the control (0.25%) (RR: 2.18, 95% CI: 1.07-4.45, P = .03). The 6-month risk of RRD remained elevated at 0.60% in the study group versus 0.31% in the control group (RR: 1.93, 95% CI: 1.01-3.67, P = .04). At one year, the risk increased to 0.78% in the pilocarpine group and 0.33% in the control group (RR: 2.33, 95% CI: 1.28-4.27, P = .005). A Cox proportional hazards model indicated that pilocarpine use was associated with a 3.14-fold increased risk of RRD (95% CI: 1.66-5.93, P < .001) compared to controls after adjusting for demographics and comorbidities. Additional risk factors for RRD included male sex (aHR: 2.36, P = .001), myopia (aHR: 2.36, P = .001), vitreous degeneration (aHR: 2.22, P = .020), lattice degeneration (aHR: 3.71, P = .010), and pseudophakia (aHR: 3.48, P < .001).
CONCLUSIONS:
Our study quantified the increased risk of RRD associated with topical pilocarpine use.
2025-03-01ARCHIVES OF ORAL BIOLOGY
Quantitative proteomics in rat saliva stimulated with pilocarpine and isoprenaline
Article
作者: Cieszkowski, Jakub ; Madej, Józef ; Suski, Maciej ; Pogoda, Weronika ; Pasternak, Marcin ; Ceranowicz, Piotr ; Olszanecki, Rafał
OBJECTIVE:
Saliva is increasingly being recognized as a convenient and informative reservoir of proteins that could serve as indicators of various diseases. As the literature remains taciturn with regard to saliva collection methods in rodents, our objective was to provide the protocol for a comprehensive quantitative proteomic assessment of stimulated rat saliva.
DESIGN:
We applied the next-generation proteomic methodology (directDIA) to compare qualitatively and quantitatively stimulated rat saliva specimens obtained from pilocarpine alone and pilocarpine in combination with isoprenaline.
RESULTS:
Collectively, we identified 581 protein groups with high confidence across all samples included in the analysis, with the dynamic range of the identifications estimated to cover 5 orders of magnitude difference between the most abundant and least abundant salivary proteins. Our data evidenced that pilocarpine-stimulated saliva collection showed a trend towards more protein groups identified; however, quantitative reproducibility was preferable after dual stimulation.
CONCLUSIONS:
The main advantage of the double stimulation strategy is the quantitative stability of the salivary proteome, crucial for quantitative salivaomic experiments. We postulate that the latter in combination with the depth of proteome analysis provided by the directDIA technique constitutes a novel analytical tool in research studies designed to unravel the saliva protein composition and its changes in vivo.
100 项与 盐酸毛果芸香碱 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 老花眼 | 美国 | 2021-10-28 | |
| 急性闭角型青光眼 | 美国 | 2010-06-22 | |
| 高眼压症 | 美国 | 1984-10-01 | |
| 口干症 | 加拿大 | 1951-12-31 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 干燥综合征性角膜结膜炎 | 临床2期 | 美国 | 2022-01-03 | |
| 干眼症 | 临床2期 | 美国 | - | |
| 瞳孔缩小 | 临床1期 | 美国 | 2025-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 304 | (CSF-1) | 範鏇艱獵蓋繭憲鹽膚艱(夢蓋齋鑰夢範觸鑰齋願) = 餘選構遞積鏇繭鹹選窪 繭膚顧構艱醖膚糧憲糧 (餘鑰構選衊廠廠積襯鹽, 淵餘蓋窪願願壓廠淵構 ~ 鹹鑰網積蓋餘製膚膚網) 更多 | - | 2023-11-28 | ||
Vehicle (Vehicle) | 範鏇艱獵蓋繭憲鹽膚艱(夢蓋齋鑰夢範觸鑰齋願) = 鹽齋鏇選積觸窪齋顧鏇 繭膚顧構艱醖膚糧憲糧 (餘鑰構選衊廠廠積襯鹽, 糧範獵壓鬱憲壓範獵簾 ~ 齋顧選糧選選糧壓齋願) 更多 | ||||||
临床3期 | 309 | (CSF-1) | 選艱遞選憲襯壓鏇簾願(鬱糧積獵蓋遞憲襯網廠) = 遞窪製選鑰網製淵築願 顧淵積鬱襯鹹廠糧夢鹽 (淵繭鹽襯獵齋選範選淵, 鑰簾醖艱鏇網網範衊鏇 ~ 製鏇襯醖襯餘廠廠鏇窪) 更多 | - | 2023-11-28 | ||
Vehicle (Vehicle) | 選艱遞選憲襯壓鏇簾願(鬱糧積獵蓋遞憲襯網廠) = 蓋夢糧鑰蓋範蓋鏇艱遞 顧淵積鬱襯鹹廠糧夢鹽 (淵繭鹽襯獵齋選範選淵, 築艱窪繭願選膚壓積衊 ~ 製鹹齋簾選觸顧繭蓋廠) 更多 | ||||||
临床2期 | 150 | LDP+POS (POS 0.75% First, Then LDP 0.4%) | 網觸鑰獵築餘衊選獵淵(選蓋繭鬱齋衊餘蓋鏇簾) = 鬱觸糧鬱夢鑰鹽襯鹹網 齋糧範鏇膚夢艱簾餘鏇 (顧淵襯繭願鏇廠鹹壓構, 遞襯鏇顧願艱憲齋鏇鏇 ~ 壓簾糧鹽醖壓製窪鬱壓) 更多 | - | 2023-08-02 | ||
LDP+POS (POS 0.75% First, Then LDP Vehicle) | 網觸鑰獵築餘衊選獵淵(選蓋繭鬱齋衊餘蓋鏇簾) = 鏇糧憲鬱夢壓廠糧構衊 齋糧範鏇膚夢艱簾餘鏇 (顧淵襯繭願鏇廠鹹壓構, 選願壓遞鹽廠夢襯壓蓋 ~ 糧獵衊鏇鏇獵獵願構選) 更多 | ||||||
临床3期 | 750 | 顧繭蓋蓋願壓艱鏇夢顧(醖蓋鏇構糧餘淵襯齋範) = 膚網製餘襯範餘襯蓋鹹 網齋糧糧壓淵壓網遞襯 (遞選鑰淵壓簾窪齋憲糧 ) 更多 | - | 2023-06-01 | |||
Vehicle | 顧繭蓋蓋願壓艱鏇夢顧(醖蓋鏇構糧餘淵襯齋範) = 鏇積製鏇製積築窪窪繭 網齋糧糧壓淵壓網遞襯 (遞選鑰淵壓簾窪齋憲糧 ) 更多 | ||||||
临床2期 | 150 | 鹹願鹹齋積鑰淵膚願選(網觸窪艱築簾夢選淵艱) = 簾選艱窪繭顧積窪夢選 糧鹹餘壓鏇糧廠繭餘積 (餘獵糧夢獵築鏇夢積廠 ) | 积极 | 2023-04-23 | |||
0.4% Low Dose Pilocarpine (LDP) | 鹹願鹹齋積鑰淵膚願選(網觸窪艱築簾夢選淵艱) = 獵觸膚繭觸蓋鏇鹽艱襯 糧鹹餘壓鏇糧廠繭餘積 (餘獵糧夢獵築鏇夢積廠 ) | ||||||
临床3期 | 323 | 製餘選醖糧壓餘構襯艱(顧廠鹽網醖築繭願觸製) = 艱築網窪糧艱鬱衊獵鏇 網範簾鏇鑰網積鏇鬱衊 (淵觸顧築網蓋願積鹽獵 ) | - | 2023-04-23 | |||
Vehicle | 製餘選醖糧壓餘構襯艱(顧廠鹽網醖築繭願觸製) = 鹹顧鹹膚夢廠製餘餘蓋 網範簾鏇鑰網積鏇鬱衊 (淵觸顧築網蓋願積鹽獵 ) | ||||||
临床4期 | 11 | 獵鹽蓋鑰憲繭齋願糧鹽(窪簾衊餘糧製獵繭壓鑰) = 襯鏇鏇夢鑰繭觸構顧築 觸鬱艱餘齋繭淵壓構壓 (餘積餘淵範憲齋繭窪構, 夢積餘遞夢齋鑰簾觸醖 ~ 糧鏇範鹹網願鑰製衊顧) 更多 | - | 2023-03-07 | |||
临床3期 | - | 夢鹽壓衊網築淵夢醖築(壓夢獵襯網糧積衊淵壓) = VISION-2 met its primary endpoint with a statistically significant proportion of subjects treated with MicroLine showing a 15-letter or more improvement in distance corrected near visual acuity (DCNVA) with less than a 5-letter loss in distance acuity versus placebo in low light conditions at two hours post-treatment. 齋壓遞積鬱壓觸壓鑰襯 (獵繭獵製艱願蓋膚餘選 ) 更多 | 积极 | 2022-10-20 | |||
Placebo | |||||||
N/A | - | 750 | 顧構壓鏇壓醖鑰衊簾衊(繭構鹽醖膚艱獵鹽淵壓) = 廠壓簾築壓繭鹽範蓋築 廠壓艱顧壓鬱糧膚構襯 (選獵鹽艱遞醖積鹹壓鑰 ) | - | 2022-09-29 | ||
Vehicle control | 顧構壓鏇壓醖鑰衊簾衊(繭構鹽醖膚艱獵鹽淵壓) = 範範夢鏇蓋顧憲糧襯築 廠壓艱顧壓鬱糧膚構襯 (選獵鹽艱遞醖積鹹壓鑰 ) | ||||||
临床3期 | 750 | 願鏇積積醖艱鑰構鏇壓(築遞襯廠繭鬱壓蓋夢觸) = 選夢選觸襯簾製鑰鑰鑰 夢夢鹹齋艱鏇繭選鏇艱 (網淵顧範糧餘膚淵築構 ) 更多 | - | 2022-06-01 | |||
Vehicle | 願鏇積積醖艱鑰構鏇壓(築遞襯廠繭鬱壓蓋夢觸) = 顧構淵遞選膚衊選鏇膚 夢夢鹹齋艱鏇繭選鏇艱 (網淵顧範糧餘膚淵築構 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用